Comparative Pharmacology
Head-to-head clinical analysis: FOLVITE versus HEXA BETALIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLVITE versus HEXA BETALIN.
FOLVITE vs HEXA-BETALIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate is reduced to tetrahydrofolate (THF) which acts as a cofactor for single-carbon transfer reactions in nucleic acid and amino acid synthesis.
Hexa-Betalin is a combination of six B vitamins (B1, B2, B3, B5, B6, B12) that act as cofactors in various enzymatic reactions involved in energy metabolism, neurotransmitter synthesis, and nerve function.
1 mg orally, intramuscularly, subcutaneously, or intravenously once daily for folic acid deficiency; for pregnant and lactating women: 0.4-0.8 mg orally once daily.
Dosage forms: Tablet 10mg, 50mg, 100mg, 250mg; Injection 50mg/mL. Usual adult dose: 100–250mg orally 1–3 times daily. Maximum 1000mg/day. IV/IM: 50–250mg every 6–8 hours as needed.
None Documented
None Documented
Terminal elimination half-life of folic acid is approximately 0.7 hours; for the active metabolite 5-methyltetrahydrofolate, half-life is 3–4 hours in plasma (tissue stores have a much longer turnover).
Terminal elimination half-life is approximately 3-5 hours in patients with normal renal function. This short half-life necessitates frequent dosing for sustained therapeutic effect. Half-life is prolonged in renal impairment.
Primarily excreted unchanged in urine (hepatic metabolism minimal); after oral doses, fecal excretion occurs via unabsorbed drug and biliary secretion of folate metabolites accounts for a minor route.
Renal excretion of unchanged drug accounts for 75-85% of the administered dose. Biliary/fecal elimination is minimal, less than 5%.
Category C
Category C
Vitamin
Vitamin